Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CombinatoRx is discontinuing the development program of its rheumatoid arthritis drug after it failed to meet the target product profile.
Subscribe to our email newsletter
The company’s clinical trial results showed that the drug candidate CRx-150 did not significantly decrease inflammation.
Alexis Borisy, president and CEO of CombinatoRx, said the level of activity observed with the drug would not be competitive within the company’s product portfolio or the rheumatoid arthritis marketplace. “Our lead RA product candidate, CRx-102, has demonstrated a much stronger clinical profile to date,” he added.